<DOC>
	<DOCNO>NCT00607711</DOCNO>
	<brief_summary>The study maximum tolerate dose safety oral palifosfamide tris capsule advance , refractory , solid tumor</brief_summary>
	<brief_title>Study Oral Palifosfamide Tris Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Subjects histological cytological confirmation advance cancer refractory standard therapy condition . 2 . Men woman ≥18 year age . 3 . Life expectancy least 12 week . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance score ≤2 ( see Appendix 4 ) . 5 . Eligible subject MUST least one measurable lesion define RECIST guideline . If measurable disease restrict solitary lesion , neoplastic nature confirm cytology/histology . Measurable lesion must NOT previously irradiate field injected biological agent . 6 . Adequate bone marrow , liver renal function assess follow laboratory requirement , conduct ≤2 week prior Baseline : Creatinine &lt; 1.5× upper limit normal ( ULN ) OR calculate creatinine clearance ≥70 cc/min Total bilirubin ≤2×ULN Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤3×ULN Granulocytes peripheral blood ≥2.0×109/L , hemoglobin ≥8.5 g/dL , platelet ≥50,000/µL 7 . Written inform consent compliance ZIOPHARM policy Human Investigation Review Committee ( IEC/IRB ) jurisdiction site . 8 . Men woman childbearing potential must use effective contraception Screening his/her duration study participation . 9 . Women childbearing potential must negative serum pregnancy test prior enter study . 1 . New York Heart Association ( NYHA ) functional Class ≥III myocardial infarction ( see Appendix 5 ) within 6 month . 2 . Uncontrolled cardiac arrhythmia asymptomatic atrial fibrillation ; QTc ≥450 msec ; ≥Grade 2 atrioventricular ( AV ) block leave bundle branch block ( LBBB ) ; document history prolong QTc . 3 . Pregnancy and/or lactation . 4 . Uncontrolled systemic infection ( documented microbiological study ) . 5 . Inadequate renal function define presence one following : Creatinine clearance ( CrCl ) &lt; 70 cc/min Serum creatinine &gt; 1.5×ULN Prior nephrectomy Urinary tract obstruction 6 . Anticancer chemotherapy immunotherapy study within 4 week study entry ( mitomycin C nitrosureas give within 6 week study entry ) . 7 . Radiotherapy study within 3 week study entry . 8 . Surgery within 4 week start study drug . 9 . Other investigational drug therapy outside trial within 4 week study entry . 10 . History invasive second primary malignancy diagnose within previous 3 year except Stage I endometrial/cervical carcinoma prostate carcinoma treat surgically , nonmelanoma skin cancer . 11 . Substance abuse , medical , psychological , social condition may interfere subject 's participation study evaluation study result . 12 . Any condition unstable could jeopardize safety subject his/her compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>